Parallax Volatility Advisers, L.P. Vertex Pharmaceuticals Inc Put Options Transaction History

Parallax Volatility Advisers, L.P.

$53.5 Billion
Q3 2024

Put Options

28 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $2.04 Million - $2.23 Million	5,000 Added 25.51%	24,600 $10.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $1.75 Million - $2.09 Million	5,100 Added 35.17%	19,600 $7.98 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $4.13 Million - $4.42 Million	12,200 Added 530.43%	14,500 $5.04 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $157,210 - $175,955	-500 Reduced 17.86%	2,300 $809,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $1.64 Million - $1.87 Million	-5,800 Reduced 67.44%	2,800 $882,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $628,672 - $707,256	-2,200 Reduced 20.37%	8,600 $2.48 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $438,128 - $488,847	1,600 Added 17.39%	10,800 $3.13 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $14.5 Million - $18.1 Million	-61,800 Reduced 87.04%	9,200 $2.59 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $15.7 Million - $18.5 Million	71,000 New	71,000 $18.5 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $5.01 Million - $6.32 Million	-28,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $1.38 Million - $1.74 Million	7,800 Added 38.05%	28,300 $6.22 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $3.72 Million - $4.16 Million	20,500 New	20,500 $3.72 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $5.91 Million - $6.62 Million	-32,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $6.11 Million - $7.21 Million	32,600 New	32,600 $6.57 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $4.55 Million - $5.31 Million	-22,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $2.84 Million - $3.31 Million	13,700 Added 165.06%	22,000 $4.73 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $1.72 Million - $2.29 Million	8,300 New	8,300 $1.96 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $351,917 - $469,352	-1,700 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $127,825 - $151,550	500 Added 41.67%	1,700 $461,000
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $428,412 - $562,020	-1,900 Reduced 61.29%	1,200 $348,000
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $3.8 Million - $4.71 Million	-19,000 Reduced 85.97%	3,100 $739,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.05 Million - $1.41 Million	6,300 Added 39.87%	22,100 $4.84 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $2.09 Million - $2.36 Million	12,600 Added 393.75%	15,800 $2.68 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $460,908 - $533,036	2,800 Added 700.0%	3,200 $588,000
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $1.67 Million - $1.99 Million	-10,200 Reduced 96.23%	400 $74,000
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $15,191 - $19,221	100 Added 0.95%	10,600 $1.76 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $83,865 - $96,370	500 Added 5.0%	10,500 $2.02 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.46 Million - $1.7 Million	10,000 New	10,000 $1.7 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.

Account